GlassScriptPhysician profile
Kakra S Gyambibi
NPI 1760641666
$1,066.42
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $107 · 2021: $960.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.84 | 2021 | |
| Merck Sharp & Dohme LLC | $226.48 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $204.84 | 2020-2021 | |
| Novo Nordisk INC | $89.15 | 2021 | |
| Lilly USA, LLC | $58.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.55 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $45.34 | 2021 | |
| Eisai INC. | $41.75 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $21.28 | 2021 | |
| Lundbeck LLC | $19.32 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.90 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kakra Gyambibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.